Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
460.28
-18.20 (-3.80%)
At close: Nov 5, 2026, 4:00 PM EST
449.98
-10.30 (-2.24%)
Pre-market: Nov 6, 2026, 8:21 AM EST
Amgen Revenue
Amgen had revenue of $10.37B in the quarter ending September 30, 2026, with 8.45% growth. This brings the company's total for the last twelve months to $38.90B, up 8.15% year-over-year. In the year 2025, Amgen had annual revenue of $36.75B with 9.95% growth. That makes Amgen the 355th largest company in the world by revenue and 125th in the United States.
Revenue (ttm)
$38.90B
Revenue Growth
+8.15%
P/S Ratio
6.40
Revenue / Employee
$1,235,016
Employees
31,500
Market Cap
248.97B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Amgen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.75B | 3.33B | 9.95% |
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
| Dec 31, 2018 | 23.75B | 898.00M | 3.93% |
| Dec 31, 2017 | 22.85B | -142.00M | -0.62% |
| Dec 31, 2016 | 22.99B | 1.33B | 6.14% |
| Dec 31, 2015 | 21.66B | 1.60B | 7.97% |
| Dec 31, 2014 | 20.06B | 1.39B | 7.43% |
| Dec 31, 2013 | 18.68B | 1.41B | 8.17% |
| Dec 31, 2012 | 17.27B | 1.68B | 10.80% |
| Dec 31, 2011 | 15.58B | 529.00M | 3.51% |
| Dec 31, 2010 | 15.05B | 411.00M | 2.81% |
| Dec 31, 2009 | 14.64B | -361.00M | -2.41% |
| Dec 31, 2008 | 15.00B | 232.00M | 1.57% |
| Dec 31, 2007 | 14.77B | 503.00M | 3.53% |
| Dec 31, 2006 | 14.27B | 1.84B | 14.79% |
| Dec 31, 2005 | 12.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| Pfizer | 63.63B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.34B |
AMGN News
- 23 hours ago - Amgen’s Repatha lowers heart attack risk 20% vs. ezetimibe in real-world study - TheFly
- 23 hours ago - REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY - PRNewsWire
- 23 hours ago - Amgen price target raised to $435 from $378 at Guggenheim - TheFly
- 1 day ago - Amgen price target raised to $530 from $500 at Scotiabank - TheFly
- 1 day ago - Amgen price target raised to $398 from $380 at Truist - TheFly
- 1 day ago - Amgen price target raised to $470 from $430 at RBC Capital - TheFly
- 1 day ago - Amgen price target raised to $520 from $480 at Oppenheimer - TheFly
- 1 day ago - Amgen price target raised to $531 from $452 at TD Cowen - TheFly